Live Breaking News & Updates on Novel combination therapy

Stay updated with breaking news from Novel combination therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Potential Combination Therapy Approaches with Ruxolitinib in Myelofibrosis

A review of recent trial data evaluating combination therapy approaches with ruxolitinib in myelofibrosis, including the rationale and potential clinical benefits associated with the use of these emerging strategies.

Myeloproliferative-neoplasms , Combination-therapy-approaches , Myelofibrosis , Novel-combination-therapy , Ruxolitinib , Jak2-inhibitor , Pelabresib , Pegylated-interferon-alpha , Navitoclax , Bcl-xl , Bcl-2

IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab

– Companies to Leverage Lead Product Candidate from IGM’s Proprietary IgM Antibody Platform with ZYNLONTA® for Novel Combination Therapy in Relapsed/Refractory B Cell NHL –– Phase 1 Trial Expected to be Initiated in 1Q23 –MOUNTAIN VIEW, Calif. & LAUSANNE, Switzerland--(BUSINESS WIRE)--IGM Biosciences, Inc. (Nasdaq:...

United-states , New-jersey , Switzerland , London , City-of , United-kingdom , American , Amanda-loshbaugh , Chris-takimoto , Lausanne-biop , Mary-ann-ondish , David-pitts

ADC Therapeutics SA: IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA in Patients with Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma

- Companies to Leverage Lead Product Candidate from IGM's Proprietary IgM Antibody Platform with ZYNLONTA for Novel Combination Therapy in Relapsed/Refractory B Cell NHL - - Phase 1 Trial Expected

United-states , New-jersey , Switzerland , London , City-of , United-kingdom , American , Amanda-loshbaugh , Chris-takimoto , Lausanne-biop , Mary-ann-ondish , David-pitts